TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01126853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix
Description: Up to three intramuscular doses of 1cc of Twinrix (combined hepatitis A/B vaccine) at 0, 1, and 6 months post-enrollment
Study: NCT01539538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil NanoTab PCA System/15 mcg
Description: 15 mcg Sufentanil NanoTab dosed sublingually q 20 minutes as needed for pain for at least 48 hours and up to 72 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine IV PCA
Description: 1 mg morphine administered IV q 6 minutes as needed for pain for at least 48 hours and up to 72 hours
Study: NCT03260309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Semi-closed loop infusion system tactic.
Description: Semi -closed loop infusion system tactic.Use volume loading test twice (before surgery and 12hrs postoperatively). Computer provides advisory hypotension treatment algorithm. Computer provides advisory anemia treatment algorithm. Programmed iv fluid and blood infusions system ,,Belmont Rapid Infuser and programmable syringe pump for adrenaline infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine infusion therapy tactic
Description: Routine re-hydration bolus before surgery. Routine treatment of hypotension. Routine treatment of anemia.
Study: NCT01657669

Intervention type: DRUG
Group type: OTHER
Intervention: Intravitreal Aflibercept injection
Description: Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection once every 8 weeks (2 months). Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of 5 letters or more from the best previous visit.
Study: NCT05154591

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Adipose-derived stromal vascular fraction cells
Description: Kidney structural and functional changes in 18 patients after 36 months of treatment with SVF cells.
Study: NCT03443375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The interventions proposed in the present trial were based on a safe and well-established exercise training program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The interventions proposed in the present trial were based on a safe and well-established exercise training program
Study: NCT02057679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin clavulanic
Description: 3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
Study: NCT04105101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Industrial passive shoulder exoskeleton
Description: Both exoskeleton types are passive shoulder exoskeletons. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Industrial passive shoulder exoskeleton
Description: Both exoskeleton types are passive shoulder exoskeletons. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Industrial passive shoulder exoskeleton
Description: Both exoskeleton types are passive shoulder exoskeletons. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions.
Study: NCT01695187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB-001 (0.3%)
Description: Topical administration at least five times throughout the day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02849678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.5% Ropivacaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision. It is the local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia. There are several studies to support this as listed in the references. Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use.
Study: NCT00679380

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02459210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLUES
Description: Cognition for learning and for understanding everyday social situations intervention described above

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: therapy and computer games
Description: Weekly psychotherapy+ computer games such as sporcle
Study: NCT00118404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuation phase cognitive therapy
Description: Continuation phase cognitive therapy included 10 sessions over 8 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation phase fluoxetine
Description: The dosage of fluoxetine was increased to 40 mg over 8 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Continuation phase pill placebo
Description: The dosage of pill placebo was increased to 40 mg over 8 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute phase cognitive therapy
Description: For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Acute phase cognitive therapy
Description: For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acute phase cognitive therapy
Description: For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.
Study: NCT04540783

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: 10 sessions of 2mA and 20 minutes tDCS. Sponges size 5x7 cm. For the sham condition, the patient will receive just 30 seconds of stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: 10 sessions of 2mA and 20 minutes tDCS. Sponges size 5x7 cm. For the sham condition, the patient will receive just 30 seconds of stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: 10 sessions of 2mA and 20 minutes tDCS. Sponges size 5x7 cm. For the sham condition, the patient will receive just 30 seconds of stimulation.
Study: NCT01494025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: Subjects underwent a diet regimen targeted to elicit a 10% weight loss. Diets were designed based on the US Dietary Guidelines with caloric deficits individualized for each subject. Aerobic exercise was monitored over approximately 14 weeks, several times per week, to elicit significantly increased VO2max.
Study: NCT02868164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: The recipient will receive healthy donor, prepared fecal installations through a Naso-gastric tube, 100 ml once a month for 6 month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Standard Treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight Reduction
Description: routine exercise for weight reduction
Study: NCT00271791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: PO, 1 mg/kg body weight, 5 days Short tapering regimen: daily reductions in the dose, 12 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: PO, Placebo, 17 days
Study: NCT01619488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Gastric Band
Description: Surgical placement of an adjustable gastric band around the upper portion of the stomach.~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction.
Study: NCT00300612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute-Melanoma Vaccine
Description: Cells will be injected intradermally every two weeks for twelve vaccinations. If the patient completes all twelve vaccinations, dosage will vary from a total of 1.3 x 109 to 3.8 x 109 HyperAcute™-Melanoma Vaccine cells administered.
Study: NCT01551108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention: advanced behavioral strategies
Description: Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents also receive additional behavioral strategies based on the Social Cognitive Theory. The strategies are delivered through weekly articles posted on the website. Text messages are designed to prompt parents to encourage their child's physical activity, remind parents of behavioral concepts presented in the articles (article tip), and motivate parents to foster behavioral change in their child.
Study: NCT06105827

Intervention type: DRUG
Group type: OTHER
Intervention: Control group
Description: Give antibiotics or diclofenac sodium suppository as needed.
Study: NCT03424213

Intervention type: OTHER
Intervention: No interventions - retrospective data collection
Description: No new patients will be consented to this study. Only retrospective data will be collected on prostatectomy specimens and correlated with health data

Intervention type: OTHER
Intervention: No interventions - retrospective data collection
Description: No new patients will be consented to this study. Only retrospective data will be collected on prostatectomy specimens and correlated with health data
Study: NCT06105827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ningmitai capsule
Description: Oral Ningmitai Capsule (produced by Guiyang Xintian Pharmaceutical Co., Ltd.), 0.38 g/capsule, 4 capsules each time, 3 times a day for 12 Weeks.
Study: NCT03424213

Intervention type: OTHER
Intervention: No interventions - retrospective data collection
Description: No new patients will be consented to this study. Only retrospective data will be collected on prostatectomy specimens and correlated with health data

Intervention type: OTHER
Intervention: No interventions - retrospective data collection
Description: No new patients will be consented to this study. Only retrospective data will be collected on prostatectomy specimens and correlated with health data

Intervention type: OTHER
Intervention: No interventions - retrospective data collection
Description: No new patients will be consented to this study. Only retrospective data will be collected on prostatectomy specimens and correlated with health data

Intervention type: OTHER
Intervention: No interventions - retrospective data collection
Description: No new patients will be consented to this study. Only retrospective data will be collected on prostatectomy specimens and correlated with health data
Study: NCT03383055

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-MVA Triplex Vaccine
Description: * CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT~* TDap administered on Day 56

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-MVA Triplex Vaccine
Description: * CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT~* TDap administered on Day 56
Study: NCT04594668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Senicapoc
Description: The intervention will consist of 50 mg enteral senicapoc administered as soon as possible after randomization and again after 24 hours
Study: NCT00952601

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified Atkins diet
Description: Low carbohydrate diet
Study: NCT03192514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Deprescribing tool
Description: Each GP of the intervention group will have exclusive access to an electronic tool that will guide them on deprescribing. The innovative electronic tool created by the researchers provide the rationale on indications for prescribing or deprescribing Benzodiazepines or/and Non-benzodiazepine hypnotics and also provides an interactive tapering suggestion integrated on a calendar.~The tool emphasizes that any decision to continue or discontinue a drug remains a shared decision between GP and the patient.~The electronic Deprescribing tool is designed to support clinical decisions
Study: NCT04843293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Olfactory stimulation
Description: Newborns in the experimental group will be given the smell of breast milk during 3 consecutive feedings and for 3 days in the morning. Smell stimulation will be started 1 minute before gavage feeding and the application of breast milk odor will continue until the feeding ends. A hand-cleaning researcher will drip 15 drops of breast milk on sterile gauze to apply the smell of breast milk. Sterile gauze dripped with breast milk will be placed as close to the newborn's nose as possible and not in contact with the newborn's skin. After the feeding of the newborn is completed, the application of the smell of breast milk will be terminated and the gauze will be removed from the incubator. A new sterile gauze will be used for each feeding, and these processes will be repeated with each smell stimulation for three days.
Study: NCT03623906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation colonoscopy
Description: Carbon dioxide insufflation colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation colonoscopy
Description: Room air insufflation colonoscopy
Study: NCT04409496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chat-based instant messaging support
Description: Subjects will receive personalised instant messaging support for 12 weeks after baseline, address the five problems that contributed to smoking relapse:~(1) lack of support for cessation, (2) negative mood or depression, (3) strong or prolonged withdrawal symptoms, (4) weight gain, and (5) smoking lapses. Updated information about the negative effect of smoking on risk of COVID-19 infection and prognosis will also be delivered.
Study: NCT06105827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined group (Ningmitai plus tamsulosin)
Description: Tamsulosin capsules, 0.2 mg/capsule, one capsule each time, once a day, were taken on the basis of Ningmitai group for 12 Weeks.
Study: NCT01996683

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: desferal, ferriprox, blood transfusion
Description: Deferiprone (75-100 mg/kg/d) and deferoxamine (20-60 mg/kg/d) aimed at achieving normal body iron stores in poly-transfued arm1.~Arm 2 will only recieve blood transfusion with no chelation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desferal, ferriprox, blood transfusion
Description: Deferiprone (75-100 mg/kg/d) and deferoxamine (20-60 mg/kg/d) aimed at achieving normal body iron stores in poly-transfued arm1.~Arm 2 will only recieve blood transfusion with no chelation
Study: NCT04128280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TUDP
Description: a surgery: transurethral dilation of prostate with a columnar balloon
Study: NCT03336671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Sinus surgery
Description: Endoscopic sinus surgery would be tailored to abnormal findings in the CT scan, as is the standard of care. Radiologists typically examine sinonasal disease of the sinuses, and they would also be requested to comment on the patency of the osteo-meatal unit, as this is a component of the Lund-McKay score. The Lund-McKay score is an objective radiologic grade of the severity of sinusitis. If there is sinus thickening, or narrowing of the OMU, endoscopic sinus surgery would be tailored to this using either balloon sinuplasty or traditional antrostomy. Patient undergoing endoscopic sinus surgery will likely have at least a maxillary antrostomy and anterior ethmoidectomy performed, with frontal sinusotomy, posterior ethmoidectomy, and sphenoidotomy performed depending on CT or endoscopy findings.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenoidectomy
Description: Adenoidectomy performed, routine, as a singular procedure not combined with any sinus surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Description: Adenoidectomy performed, routine, as a singular procedure not combined with any sinus surgery.
Study: NCT01774604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 100 mg Indomethacin PR x 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03697148

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multiparametric Magnetic Resonance Imaging
Description: Undergo mpMRI
Study: NCT04116671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromechanical Gait Assist
Description: A hybrid powered knee orthosis combined with surface muscle stimulation to assist walking.
Study: NCT02204878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib Sodium
Description: Dynastat 40mg was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. Dynastat 40mg Q12h will be given within 72 hours after surgery
Study: NCT03727529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill + VR
Description: Patients will walk on the tredmill with the virtual reality headset. Patients will walk in a straight line in a coherent, immersive and simple virtual environment. Before the first session, a 15-minute session will focus on patient familiarization with iVR
Study: NCT04128280

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TUIB
Description: a surgery: transurethral incision of bladder neck
Study: NCT03727529

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Description: Patients will walk on the treadmill without iVR. Patients will also receive a short familiarization to the treadmill before strating the experimentation.
Study: NCT02616406

Intervention type: DEVICE
Intervention: GENEactiv
Description: To wear a monitoring device for a period of time prior to surgery and post surgery
Study: NCT04409496

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS message support
Description: Subjects will receive regular SMS on generic smoking cessation for 3 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help booklet
Description: Subjects will receive a standard self-help booklet on smoking relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help booklet
Description: Subjects will receive a standard self-help booklet on smoking relapse prevention.
Study: NCT02043509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MiQuit
Description: MiQuit is an automated responsive text message support programme lasting 12 weeks which provides tailored smoking cessation support and advice to the participant's mobile phone. This support includes motivational messages, advice about preparing for a quit attempt, how to manage cravings and withdrawal, dealing with trigger situations, information about how smoking affects babies and general encouragement.
Study: NCT03672552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFWP and Improved Oral Care
Description: The FFWP with dental hygiene participants will have assessments for swallowing and oral health then proceed to have a dental hygienist cleaning. This intervention group will have supervised and assisted tooth brushing by nursing staff before taking plain (thin) unmodified water and between meals.
Study: NCT03732157

Intervention type: PROCEDURE
Intervention: outpatient management of parathyroidectomy
Description: The patient is discharged from hospital the same day of the parathyroidectomy intervention instead of conventional management (stay overnight in hospital)

Intervention type: PROCEDURE
Intervention: conventional management of parathyroidectomy
Description: The patient stays overnight in hospital after intervention